Erkang Pharmaceutical released its 2026 half-year report on August 26. The company's first-half operating revenue was 568 million yuan, down 16.8% year on year, but net profit attributable to the parent was 44.47 million yuan, up 18.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 41.19 million yuan, up 24.7% year on year. Net operating cash flow was negative 154 million yuan, down 436.0% year on year, and earnings per share were 0.0216 yuan. In the second quarter, the company's operating revenue was 320 million yuan, down 2.5% year on year, and net profit attributable to the parent was 31.36 million yuan, a sharp year-on-year increase of 229.3%. As of the end of the second quarter, the company's total assets were 4.98 billion yuan, up 2.4% from the end of the previous year, and net assets attributable to the parent were 4.022 billion yuan, down 0.3% from the end of the previous year. The company's business covers excipients, active pharmaceutical ingredients, finished drugs, and new energy materials. In excipients, it continues to develop products such as pharmaceutical ethanol and pharmaceutical glycerin. In new energy materials, it is increasing its layout in the lithium carbonate industry chain and adopting a production-based-on-sales strategy to respond to market changes.
Hunan Er Kang PharmaceuticalNet profit attributable to parent rose 18.2% year on year, with Q2 profit up 229.3%.
